PRELIMINARY SAFETY AND CLINICAL ACTIVITY RESULTS FROM A PHASE IB STUDY OF ATEZOLIZUMAB + BEVACIZUMAB IN HEPATOCELLULAR CARCINOMA

OUTCOMES IN PATIENTS (PTS) WITH HEPATITIS B VIRUS (HBV) IN THE PHASE 3 CELESTIAL TRIAL OF CABOZANTINIB (C) VERSUS PLACEBO (P) IN ADVANCED HEPATOCELLULAR CARCINOMA (HCC)

SORAFENIB WITH VERSUS WITHOUT CONCURRENT CONVENTIONAL TRANSARTERIAL CHEMOEMBOLIZATION (CTACE) IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC): RESULTS FROM A MULTICENTER, OPEN- LABEL, RANDOMIZED, CONTROLLED PHASE III STAH TRIAL

PROGRESSION FREE SURVIVAL AS A SURROGATE MARKER FOR SURVIVAL IN PATIENTS TREATED WITH TACE: A SUB-STUDY OF THE TACE 2 TRIAL

RAMUCIRUMAB VERSUS PLACEBO AS SECOND-LINE TREATMENT IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA AND ELEVATED BASELINE ALPHA-FETOPROTEIN FOLLOWING FIRST-LINE SORAFENIB (REACH-2): A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

OUTCOMES OF PATIENTS (PTS) WITH HEPATOCELLULAR CARCINOMA (HCC) TREATED WITH TRANSARTERIAL CHEMOEMBOLIZATION (TACE): GLOBAL OPTIMIS FINAL ANALYSIS

RANDOMIZED, OPEN LABEL, MULTICENTER, PHASE II TRIAL OF TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE) THERAPY IN COMBINATION WITH SORAFENIB AS COMPARED WITH TACE ALONE IN PATIENTS WITH HEPATOCELLULAR CARCINOMA: TACTICS TRIAL

OVERALL SURVIVAL (OS) UPDATE: 2-YEAR FOLLOW-UP FROM THE PHASE 3 RESORCE TRIAL OF REGORAFENIB FOR PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) PROGRESSING ON SORAFENIB

EXPLORATORY ANALYSES OF THE BILCAP STUDY

FIRST-IN-HUMAN, FIRST-IN-CLASS PHASE I STUDY OF MTL-CEBPA, A SMALL ACTIVATING RNA (SARNA) TARGETING THE TRANSCRIPTION FACTOR C/EBP- ˜ IN PATIENTS WITH ADVANCED LIVER CANCER

COMBINATION OF CHEMOTHERAPY AND YTTRIUM-90 GLASS MICROSPHERES SELECTIVE INTERNAL RADIATION THERAPY (SIRT) IN FIRST-LINE TREATMENT OF INOPERABLE CHOLANGIOCARCINOMA (MISPHEC STUDY)

INDEPENDENT IMAGING REVIEW (IIR) RESULTS IN A PHASE 3 TRIAL OF LENVATINIB (LEN) VS SORAFENIB (SOR) IN FIRST- LINE TREATMENT OF PATIENTS (PTS) WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (UHCC)

PROGNOSTIC VALUE OF THE NEUTROPHIL-TO-LYMPHOCYTE RATIO IN PATIENTS WITH INTERMEDIATE STAGE HEPATOCELLULAR CARCINOMA: EXPLORATORY ANALYSIS OF THE TACE-2 TRIAL

DIFFERENCES IN PRESENTATION AND MANAGEMENT PATTERNS IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) BETWEEN CHINA AND SINGAPORE: INITIAL DATA FROM THE HCC REGISTRY IN ASIA

URINE PROTEIN:CREATININE RATIO (UPCR) VS 24-H URINE PROTEIN FOR THE MANAGEMENT OF PROTEINURIA: RESULTS FROM A PHASE 3 STUDY OF LENVATINIB (LEN) VS SORAFENIB (SOR) IN HEPATOCELLULAR CARCINOMA (HCC) TR